Johnson & Johnson’s (J&J) Caplyta (lumateperone) plus antidepressants nearly doubled the likelihood of remission after six ...

While the FDA came out on top over the EMA in terms of approvals, both agencies greenlighted fewer new drugs than in 2024.

Agenus has completed a $141m strategic collaboration with Zydus Lifesciences to accelerate the global development and ...

AbbVie’s lost exclusivity for Humira is offset by immunology and neurology sales, diversified by its emerging oncology ...

InterAx Biotech has entered into a strategic research collaboration and licensing agreement with Alveus Therapeutics to ...

Public markets are showing early signs of reopening, as Q4 2025 saw a 157% increase in IPO deal volume compared to Q4 2024.

Eli Lilly highlighted 2025 as the rollout year for obesity drugs, with Mounjaro at the forefront of its weight-loss portfolio ...

Novavax’s president and CEO reviewed the company’s successes in 2025 and shared its growth strategy for 2026 and beyond at a ...

To thrive beyond rare disease, cell and gene therapy developers must scale-up manufacturing and commercialisation.

Jazz Pharmaceuticals has sold a priority review voucher (PRV) for $200m, suggesting the uptick in market prices for the ...

Novo Nordisk is positioning itself as a long‑term leader across multiple obesity segments rather than relying on a single ...

The company will prioritise investment for in-house innovation over large M&A deals, bucking the trend across pharma.